Objective: Despite advancements in vascular surgery, the mortality among peripheral arterial disease (PAD) patients undergoing major amputations remains high. While a large body of evidence has previously covered survival rates after major amputation, there is less evidence regarding the associated survival penalty from an epidemiological perspective. The present analysis aimed at quantifying the survival disadvantage after major lower limb amputation while investigating which factors are associated with mortality in this patient cohort. Methods: Data from 246 PAD patients undergoing major amputations were retrospectively collected and matched with mortality records from the Austrian National Death Registry. Life expectancy was estimated using population-based life tables, and differences between observed and expected survival were analyzed across subgroups. Results: The median follow-up was 492 days (Q1–Q3: 73–1438), and 82.5% (n = 203) of patients died, with cardiovascular events being the leading cause (41%). A profound discrepancy between estimated (4697 days, Q1–Q3: 2962–6236) and observed survival (457 days, Q1–Q3: 73–1438, p < 0.001) was seen. In men, an associated median survival penalty of 11.2 years was observed, equivalent to a proportionate reduction in life expectancy of over 90%, while the difference in women was 8.7 years, equaling a reduction of 84.6%. In a multiple regression model, 1 year in life expectancy was associated with a survival penalty of −0.96 years, thereby affecting younger patients with the highest life expectancies the most. Conclusions: Major amputation in PAD patients is associated with a significant reduction in survival compared to standardized mortality rates in the general population. The survival disadvantage exceeds 70% of estimated survival times in over 70% of patients. Elevated mortality rates after major amputation in PAD patients should not be interpreted as a causal relationship but as a surrogate for impaired systemic cardiovascular health.

Introduction: Fenestrated endovascular aortic repair (FEVAR) has become a popular custom-made treatment option for juxtarenal and pararenal aneurysms. It has been previously investigated whether octogenarians as a distinct subgroup are at increased risk for adverse outcomes after FEVAR. With diverging results and an inconclusive understanding of age as a risk factor in general, an analysis of the historical data of a single center was conducted to add to the available body of evidence and further investigate the effect of age as a continuous risk factor. Methods: A retrospective data analysis of a prospectively maintained single-center database of all patients who underwent FEVAR at a single department of vascular surgery was performed. The main endpoint was post-operative survival. In addition to association analyses, potential confounders such as co-morbidities, complication rates, or aneurysm diameter were examined. In terms of sensitivity analyses, logistic regression models were created for the dependent variables of interest. Results: During the observation period from April 2013 to November 2020, 40 patients over the age of 80 and 191 patients under the age of 80 were treated by FEVAR. The 30-day survival showed no significant difference between the groups (95.1% in octogenarians and 94.3% in patients under 80 years of age). The sensitivity analyses conducted also showed no difference between the two groups, and complication and technical success rates were comparable. The aneurysm diameter was 67 ± 13 mm in the study group and 61 ± 15 mm in those under 80 years of age. Additionally, the sensitivity analyses showed that age as a continuous variable exhibits no effect on the outcomes of interest. Discussion: In the present study, age was not associated with adverse peri-operative outcomes after FEVAR, including mortality, lower technical success rates, complications, or length of hospital stay. Essentially, the most highly associated factor with hospital and ICU length of stay was time spent in surgery. However, octogenarians had a significantly larger aortic diameter at the time of treatment, which might indicate the potential introduction of bias by pre-interventional patient selection. Nevertheless, the usefulness of research on octogenarians as a distinct subgroup might be questionable regarding the scalability of results, and future studies might focus on age as a continuous risk factor instead.

Objectives: The choice of vascular access continues to be a critical component in the management of hemodialysis patients. Despite the international consensus favoring arteriovenous (AV) fistulas, the use of central venous catheters (CVCs) remains prevalent, with substantial variations across countries and even among dialysis centers within the same region. This study examines the prevalence of CVC use among chronic hemodialysis (CHD) patients in Vienna, Austria, and explores inter-center differences. Methods: A cross-sectional analysis was conducted on patients receiving CVC-based CHD in Vienna as of March 2023. Patient demographics, comorbidities and their hemodialysis history were collected. Additionally, a subset of the population underwent vascular access (VA) mapping to assess eligibility for AV fistula (AVF) or AV graft (AVG) creation. Results: A total of 335 patients received CVC-based hemodialysis, equaling a CVC proportion of 42.5%. 191 (57.0%) patients on CVC-based CHD gave their consent to record their clinical data and vascular access history. Of the 191 included patients, 61 gave their consent to receive VA mapping. Of the 61 patients who received VA mapping, 60 (98.4%) were eligible for an upper extremity AVF or AVG. There was no significant difference regarding patient demographics, dialysis vintage, history of previous AVF or AVG or Charlson Comorbidity Index between the mapping and non-mapping group. The odds ratio of having a CVC in the absence of in-house vascular surgery was 3.41 (95% CI: 2.31–5.02, p-value < 0.001) compared to patients with in-house vascular surgery. Conclusions: The majority of patients that consented to ultrasound VA mapping fulfilled vascular requirements for AVF or AVG creation. Our study highlights the potential to decrease the prevalence of CVC-based CHD in Vienna that could translate to a reduction in CVC-associated complications.

Introduction: Apart from their high burden of disease, major amputations, especially due to macro- and microangiopathic malperfusion, persist to inflict a relevant socioeconomic impact in most geographic regions. It has been repeatedly shown that lower extremity amputations are associated with impaired post-operative survival. In the present study, we investigated whether metrics derived from routine laboratory studies after amputation are associated with post-operative survival. Methods: In this retrospective single-center analysis, 244 patients undergoing lower extremity amputation between 2012 and 2016 were included. Serum hemoglobin and leukocyte counts of the first 21 post-operative days as well as derived metrics were analyzed in addition to clinical and demographic variables. Kaplan–Meier estimates and adjusted Cox regressions were fitted including relevant parameters. Results: In summary, 71.3% of patients underwent transtibial and 28.7% transfemoral amputations. The most frequent post-operative complications were wound-related (43.0%). Long-term survival analyses showed that advanced age and higher ASA class were significantly associated with reduced post-operative survival, while no significant survival differences were observed based on sex, smoking history, or type of amputation. Laboratory parameter analysis showed impaired peri-operative outcomes in patients with elevated leukocyte counts, with leukocyte-derived metrics showing significant associations with long-term survival after adjustment for age and ASA class. Conclusions: This study highlights the potential of routine laboratory parameter-derived metrics in predicting mortality after major lower extremity amputations in PAD patients.

Background: Ehlers–Danlos syndrome (EDS), Marfan syndrome (MFS), and Loeys–Dietz syndrome (LDS) are connective tissue disorders frequently associated with vascular aneurysm formation, dissections, and subsequent major complications. Regular imaging surveillance is recommended for these conditions. However, no guidelines currently exist regarding imaging modality or surveillance intervals. Methods: This retrospective single-center observational study analyzed clinical and imaging data of patients attending an outpatient clinic for vascular connective tissue disorders between August 2008 and January 2024. Imaging (1424 data points in total) and clinical data were extracted from electronic health records. Analysis primarily included a comparison of vessel diameter progression across imaging modalities, with an additional review of the clinical history of vascular events. Results: In total, 19 patients with vascular connective tissue disorders (vCTDs) underwent consultations at our outpatient clinic. Nine (47.4%) patients experienced vascular events, while two (10.5%) passed away during the study period. Multimodal imaging surveillance revealed a tendency towards arterial diameter increase. Consistent ultrasound monitoring provided more reliable diameter progression data for the same arterial segment than a combination of imaging modalities. Temporal analysis indicated a tendency for the continuous growth of the abdominal aorta, the common and internal carotid artery, and the common femoral and popliteal artery. Conclusion: The study highlights the importance of standardized, modality-specific imaging protocols in monitoring patients with vCTDs. The variability in disease progression among these patients further complicates surveillance strategies, contemplating the need for individualized approaches. Further research and prospective multicenter studies are required to refine and improve monitoring protocols.

Background/Objectives: Hemodialysis (HD) is a life-sustaining treatment for an increasing number of patients around the globe. The options for vascular access (VA) in HD are arteriovenous fistulas (AVFs), arteriovenous grafts (AVGs), and central venous catheters (CVCs). AVFs are historically associated with better long-term outcomes. Recently, international guidelines have shifted to a more individualized approach driven by evidence that patient-specific factors influence the success of AVF creation. The initial “Vienna ACTS NOW” study revealed significant inter-center variability in CVC prevalence in Vienna. This two-year follow-up aimed to document the continuing variability in CVC-based HD management and to monitor the clinical outcomes and cost associated with an attempted conversion to AVF/G. Methods: This multi-center cohort study collected data (March 2023 to March 2025) on 153 CVC-based HD patients from six Viennese institutions. Primary endpoints included VA-related events and patency; the secondary endpoint was overall mortality. Costs were calculated using the Austrian Catalogue for Medical Services (MEL). Results: Overall, 28 (18.3%) out of 153 patients underwent AVF/G surgery, and 20 (71.4%) achieved successful cannulation. A total of 12 surgical and 14 endovascular interventions were performed to either support VA maturation or maintain patency. The median hospital admission was 3 days for VA creation and 4 days for later interventions. VA creation in patients that did not require later interventions cost 3130.44 € per patient, and it cost 11,893.02 € in patients that did. The proportion of AVF/G creation attempts varied from 0% to 40.9% between centers. Patients who underwent VA-creating surgery had a better rate of survival after two years compared to patients who did not undergo VA-creating surgery. (86.2% vs. 63.3% p < 0.02). Overall, 6.3% of deaths were related to VA management. Conclusions: Patient-specific characteristics and the capability of the healthcare system to timely detect and treat CKD might influence the outcome of patients. The proportion of CVC- and AVF/G-based HD might therefore be associated with the level of access patients have to the healthcare system and the efficiency of the care network. Our own data point towards a difference in CVC use between different centers in Vienna, not solely driven by patient characteristics, but by locally available resources and differences in policies.